
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. is positioned for growth as the demand for cell and gene therapies continues to rise, leading to expectations of increased commercial revenue and clinical trial activity driven by advancements in oncology and rare diseases. In the most recent quarter, the company's total revenue reached $44 million, demonstrating a 15% year-over-year growth on a constant currency basis, slightly up from 14% in the previous quarter. The ongoing upward trajectory in the number of approved therapies and those in development signals a robust pipeline, reinforcing a favorable outlook for CryoPort in the life sciences market.
Bears say
CryoPort Inc. is experiencing a decline in momentum, as evidenced by its Life Sciences Services revenue growth of 16%, which has decreased from 21% in the previous quarter. The adjusted EBITDA margin remains negative at (1.5%), reflecting challenges in profitability and performing below consensus expectations. Additionally, the company faces a bear case scenario driven by slower revenue growth linked to fewer approvals in the cell and gene therapy space, compounded by reduced demand for MVE freezers, leading to lowered earnings projections for 2026.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares